Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration

Nucleic Acid Therapeutics

Volumn 22, Issue 4, 2012, Pages 255-264

  Thompson, James D ^a   Kornbrust, Douglas J ^b   Foy, Jeffrey W D ^a   Solano, Elisabeth C R ^a   Schneider, David J ^a   Feinstein, Elena ^a   Molitoris, Bruce A ^c   Erlich, Shai ^a  

^a QBI Enterprises Ltd   (Israel)

^b Preclinsight   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTECTIVE AGENT; PROTEIN P53; SMALL INTERFERING RNA; SMALL INTERFERING RNA I5NP; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; FEMALE; HEART SURGERY; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REPERFUSION INJURY; RNA INTERFERENCE;

ADMINISTRATION, INTRAVENOUS; ANIMALS; AREA UNDER CURVE; DRUG EVALUATION, PRECLINICAL; FEMALE; KIDNEY; MACACA FASCICULARIS; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY; RNA, MESSENGER; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865442084     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2012.0371     Document Type: Article

References (18)

1. BROWN, D.A., KANG, S.H., GRYAZNOV, S.M., DEDIONISIO, L., HEIDENREICH, O., SULLIVAN, S., XU, X., and NERENBERG, M.I. (1994). Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269, 26801-26805. (Pubitemid 24332875)
2. BURNS, V.E., EDWARDS, K.M., RING, C., DRAYSON, M., and CARROLL, D. (2008). Complement cascade activation after an acute psychological stress task. Psychosom. Med. 70, 387-396.
3. CROOKE, S.T. (1998). Antisense therapeutics. Biotechnol. Genet. Eng. Rev. 15, 121-157. (Pubitemid 28185141)
4. CZAUDERNA, F., FECHTNER, M., DAMES, S., AYGUN, H., KLIPPEL, A., PRONK, G.J., GIESE, K., and KAUFMANN, J. (2003). Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31, 2705-2716. (Pubitemid 37442115)
5. GEARY, R.S., LEEDS, J.M., FITCHETT, J., BURCKIN, T., TRUONG, L., SPAINHOUR, C., CREEK, M., LEVIN, A.A. (1997a). Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf- 1 kinase expression. Drug Metab, Dispos. 25, 1272-1281. (Pubitemid 27490672)
6. GEARY, R.S., LEEDS, J.M., HENRY, S.P., MONTEITH, D.K., and LEVIN, A.A. (1997b). Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des. 12, 383-393. (Pubitemid 27292374)
7. HENRY, S.P., MONTEITH, D.K., and LEVIN, A.A. (1997). Effects of intravenous infusion of phosphorothioate oligonucleotides on coagulation, complement activation and hemodynamics. Nucleosides Nucleotides 16, 1673-1676. (Pubitemid 27494544)
8. HENRY, S., STECKER, K., BROOKS, D., MONTEITH, D., CONKLIN, B., and BENNETT, C.F. (2000). Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther. 292, 468-479. (Pubitemid 30067408)
9. LEE, P.A., BLATT, L.M., BLANCHARD, K.S., BOUHANA, K.S., PAVCO, P.A., BELLON, L., and SANDBERG, J.A. (2000). Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice. Hepatology 32, 640-646.
10. LEVIN, A., MONTEITH, D.K., LEEDS, J.M., NICKLIN, P.L., GEARY, R.S., BUTLER, M., TEMPLIN, M.V., and HENRY, S.P. (1998). Toxicity of oligonucleotide therapeutic agents. In Handbook Exp. Pharmacol. G.V.R. Born et al., ed. (Springer- Verlag, Berlin), pp. 169-215.
11. MASARJIAN, L., DE PEYSTER, A., LEVIN, A.A., and MONTEITH, D.K. (2004). Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury. Oligonucleotides 14, 299-310. (Pubitemid 40144367)
12. MOLITORIS, B.A., DAGHER, P.C., SANDOVAL, R.M., CAMPOS, S.B., ASHUSH, H., FRIDMAN, E., BRAFMAN, A., FAERMAN, A., ATKINSON, S.J., et al. (2009). siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J. Am. Soc. Nephrol. 20, 1754-1764.
13. MONTEITH, D.K., and LEVIN, A.A. (1999). Synthetic oligonucleotides: the development of antisense therapeutics. Toxicol. Pathol. 27, 8-13. (Pubitemid 29075737)
14. PARRY, T.J., BOUHANA, K.S., BLANCHARD, K.S., PAVCO, P.A., and SANDBERG, J.A. (2000). Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens. Curr. Issues Mol. Biol. 2, 113-118.
15. PHILLIPS, J.A., CRAIG, S.J., BAYLEY, D., CHRISTIAN, R.A., GEARY, R., NICKLIN, and P.L. (1997). Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol. 54, 657-668. (Pubitemid 27404625)
16. SANDBERG, J.A., BOUHANA, K.S., GALLEGOS, A.M., AGRAWAL, A.B., GRIMM, S.L., WINCOTT, F.E., REYNOLDS, M.A., PAVCO, P.A., and PARRY, T.J. (1999). Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse. Antisense Nucleic Acid Drug Dev. 9, 271-277. (Pubitemid 29361061)
17. STARR, J.L., and SELLS, B.H. (1969). Methylated ribonucleic acids. Physiol. Rev. 49, 623-669.
18. VAN DE WATER, F.M., BOERMAN, O.C., WOUTERSE, A.C., PETERS, J.G., RUSSEL, F.G., and MASEREEUW, R. (2006). Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab. Dispos. 34, 1393-1397. (Pubitemid 44079881)